NCT03204097 is a Phase 2/Phase 3 clinical trial of Alendronate in Chronic Periodontitis, sponsored by Government Dental College and Research Institute, Bangalore.

Who is sponsoring NCT03204097?

NCT03204097 is sponsored by Government Dental College and Research Institute, Bangalore.

What drugs are being tested in NCT03204097?

Interventions in NCT03204097: placebo, Alendronate, Aloe Vera.

What condition does NCT03204097 study?

NCT03204097 studies Chronic Periodontitis.

Is NCT03204097 still recruiting?

NCT03204097 is currently completed. Last updated 28 June 2017.

Last reviewed 2017-06-28 · How we verify

NCT03204097

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1% Alendronate and Aloevera Gel Local Host Modulating Agents in Chronic Periodontitis Subjects With Class II Furcation Defects: A Randomized Controlled Clinical Trial

Completed Phase 2/Phase 3 Last updated 28 June 2017

What this trial tests

Phase 2/Phase 3 trial testing placebo in Chronic Periodontitis in 90 participants. Completed in 1 February 2017.

Timeline

1 March 2016

Primary endpoint
1 February 2017

1 February 2017

Quick facts

Lead sponsor	Government Dental College and Research Institute, Bangalore
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	90
Start date	1 March 2016
Primary completion	1 February 2017
Estimated completion	1 February 2017

Drugs / interventions tested

placebo
Alendronate — full drug profile →
Aloe Vera — full drug profile →

Conditions studied

Chronic Periodontitis — all drugs for Chronic Periodontitis →

Sponsor

Government Dental College and Research Institute, Bangalore

Who can join

Adults 25 to 50, any sex, with Chronic Periodontitis. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change in Bone defect depth
Time frame: baseline, 6 & 12 months
Assessed in percentage

Sponsor's own description

Alendronate (ALN), commonly use bisphosphonates is proposed to have osteostimulative properties in vivo and in vitro, as shown by an increase in the matrix formation, and acts as a potent inhibitor of bone resorption. AV widely known for its wound healing, analgesic, antioxidant, antibacterial, antiviral, antifungal, immune boosting and significant anti-inflammatory properties. The present study aims to explore the efficacy of 1% ALN and AV gel as a local drug delivery as an adjunct to scaling and root planing (SRP) for the treatment of degree II furcation defects

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Alendronate

Trials testing the same drug.

NCT07216794 — Small Trial of Alendronate Impact on the Reservoir of HIV · Phase 2 · not yet recruiting
NCT06772792 — A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Pa · Phase 1 · completed
NCT06264609 — Precision Medicine Approach for Osteoporosis - Follow Up Study · Phase 4 · enrolling by invitation
NCT06264401 — Treatment Exercises With Core Stability and Dynamic Resistance Exercise for Postmenopausal Women With Osteoporosis · NA · completed
NCT05645289 — Efficacy and Safety of Minodronate in Patients With Low Back Pain · Phase 4 · unknown

Other recruiting trials for Chronic Periodontitis

Currently open trials in the same condition.

NCT06893107 — Study on Treatment Results and Bone Changes After Replanting Severely Affected Teeth - A Before-and-After Study. · NA · recruiting
NCT05275192 — Utilization of a Videoscope in Periodontal Regeneration · NA · recruiting
NCT03741374 — Minimally-invasive Non-surgical Therapy of Intrabony Defects · NA · active not recruiting
NCT03553095 — Comparing Inflammatory Markers in Patients With and Without Depression With Chronic Periodontitis · NA · active not recruiting

Other Government Dental College and Research Institute, Bangalore trials

Trials by the same sponsor.

NCT03738514 — Comparison of Efficacy of 5% Fluorocalcium Phosphosilicate Dentifrice and Potassium Nitrate Dentifrice on Dentinal Hyper · Phase 2 · completed
NCT03741309 — Comparison of Clinical Efficacy of a Dentifrice Containing 5% Fluoro Calcium Phosphosilicate to a Dentifrice Containing · Phase 2 · completed
NCT03745300 — Comparative Evaluation Of 1.2% Atorvastatin and 1.2% Simvastatin Gel Local Drug Delivery And Redelivery In Chronic Perio · Phase 2, PHASE3 · completed
NCT03204058 — Locally Delivered Metformin & Rosuvastatin for Treatment of Intrabony Defects in Chronic Periodontitis · Phase 2, PHASE3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03204097 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Government Dental College and Research Institute, Bangalore
Last refreshed: 28 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03204097.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing